drugset / Trial / NCT03897946

Evaluating Immunogenicity of a Birth Dose of HBV Vaccine in the DRC

NCT03897946 ↗

RandomizedParallel-groupDouble-blindPrevention

Summary

This project will assess the immunogenicity of a birth dose of hepatitis B vaccine in hepatitis B-exposed and hepatitis B-unexposed infants in Kinshasa, Democratic Republic of the Congo. A better understanding of the protection offered by the addition of birth dose vaccine to the EPI schedule is necessary in order to promote universal adoption of a birth dose vaccine in the DRC and throughout SSA.

Timeline

Start
2019-08-20
Primary completion
2021-02-05
Completion
2021-02-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Birth dose hepatitis B vaccine Vaccine — —